Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALTB-268 in Healthy Volunteers
NCT05723692Phase 1Completed
- Sponsor
- AltruBio Inc.
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing ALTB-268 with Placebo (2 arms). Primary endpoint: Incidence of ALTB-268 Treatment-Emergent Adverse Events at Day 120. Started Jan 2023; status: completed.
02
Drugs
leiolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05723692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723692.